Abstract
This is the third article in a four-part series on new radiopharmaceuticals. Upon completion of this article, the technologist should be able to (1) identify the benefits of imaging with MAG3, (2) recognize the different properties of the imaging agents DTPA, OIH, and MAG3, (3) utilize developed imaging techniques, and (4) identify some abnormal conditions.